A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJean‐Charles Soria, Michael Millward, Hui Gan et al.|Annals of Oncology|2016Cited by 145
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.Jean‐Charles Soria, Michael Millward, Hui Gan et al.|Journal of Clinical Oncology|2012Cited by 14
610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent MesotheliomaJean‐Charles Soria, M.J. Millward, Ruth Plummer et al.|European Journal of Cancer|2012Cited by 8
Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors.Angelica Fasolo, Luca Gianni, Rodrigo Ruiz-Soto et al.|Journal of Clinical Oncology|2010Cited by 1